SCHEMBL3586815

SCHEMBL3586815

Cc1cc(/C=C/C(F)(F)F)ccc1C(=O)Nc1cnc2cc(CO)cnc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 4/20 0.39
KDR P35968 4/20 0.38
SCN10A Q9Y5Y9 1/20 0.36
LRRK2 Q5S007 1/20 0.35
KIT P10721 2/20 0.35
CTNNB1 P35222 1/20 0.34
TCF7L2 Q9NQB0 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
MITF O75030 1/20 0.34
XBP1 P17861 1/20 0.34
RAB9A P51151 1/20 0.34
PAX8 Q06710 1/20 0.34
KLF5 Q13887 1/20 0.34
ABL1 P00519 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3586822 1.00 TRPV1 (0.39) TRPV1KDRSCN10ALRRK2KIT
SCHEMBL13544332 0.92 KDR (0.38) TRPV1KDRLRRK2KITCTNNB1
SCHEMBL3590895 0.90 TRPV1 (0.43) TRPV1KDRLRRK2NPC1RAB9A
SCHEMBL5034669 0.90 KDR (0.42) TRPV1KDRCTNNB1TCF7L2MEN1
SCHEMBL3590891 0.90 TRPV1 (0.43) TRPV1KDRLRRK2NPC1RAB9A
SCHEMBL5034665 0.90 KDR (0.42) TRPV1KDRCTNNB1TCF7L2MEN1
SCHEMBL13544065 0.88 TRPV1 (0.41) TRPV1KDRCTNNB1TCF7L2KDM4E
SCHEMBL13544305 0.87 TRPV1 (0.42) TRPV1KDRLRRK2KITMEN1
SCHEMBL3583585 0.86 TRPV1 (0.37) TRPV1KDRLRRK2KITMEN1
SCHEMBL3583591 0.86 TRPV1 (0.37) TRPV1KDRLRRK2KITMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004222-A1 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same RENOVIS, INC. (US) 2010-01-07 US claimed
US-20100004222-A1 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same RENOVIS, INC. (US) 2010-01-07 US disclosed
US-20100004222-A1 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same RENOVIS, INC. (US) 2010-01-07 US disclosed
WO-2007100758-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004222-A1 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same TRPV1, TRPA1, TRPV2 TRPV1 1/4885KDR 2563/4885SCN10A 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.